Sabrina Weißmüller

Dr. Sabrina Weißmüller

Biotest AG

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 December 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
Fabian BohländerFabian Bohländer
Fabian Bohländer
SWSabrina Weißmüller
Sabrina Weißmüller
DRDennis Riehl
Dennis Riehl
MGMarcus Gutscher
Marcus Gutscher
JSJörg Schüttrumpf
Jörg Schüttrumpf
SFStefanie Faust
Stefanie Faust
In comparison to human immunoglobulin (Ig) G, antibodies of IgA class are not well investigated. In line with this, the functional role of the IgA component in IgM/IgA-enriched immunoglobulin preparations is also largely unknown. In recent years, powerful anti-pathogenic and immunomodulatory properties of human serum IgA especially on neutrophil function were unraveled. Therefore, the aim of our work is to investigate functional aspects of the trimodulin IgA component, a new plasma-derived polyvalent immunoglobulin preparation containing ~56% IgG, ~23% IgM and ~21% IgA. The functional role of IgA was investigated by analyzing the interaction of IgA with FcαRI, comparing trimodulin with standard intravenous IgG (IVIG) preparation and investigating Fc receptor (FcR)-dependent functions by excluding IgM-mediated effects. Trimodulin demonstrated potent immunomodulatory, as well as anti-pathogenic effects in our neutrophil model (neutrophil-like HL-60 cells). The IgA component of trimodulin was shown to induce a strong FcαRI-dependent inhibitory immunoreceptor tyrosine-based activation motif (ITAMi) signaling, counteract lipopolysaccharide-induced inflammation and mediate phagocytosis of Staphylococcus aureus. The fine-tuned balance between immunomodulatory and anti-pathogenic effects of trimodulin were shown to be dose-dependent. Summarized, our data demonstrate the functional role of IgA in trimodulin, highlighting the importance of this immunoglobulin class in immunoglobulin therapy.

14 July 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
CSCarolin Schmidt
Carolin Schmidt
SWSabrina Weißmüller
Sabrina Weißmüller
Fabian BohländerFabian Bohländer
Fabian Bohländer
MGMatthias Germer
Matthias Germer
MKMartin König
Martin König
JSJörg Schüttrumpf
Jörg Schüttrumpf
Activation of the complement system is important for efficient clearance of a wide variety of pathogens via opsonophagocytosis, or by direct lysis via complement-dependent cytotoxicity (CDC). However, in severe infections dysregulation of the complement system contributes to hyperinflammation. The influence of the novel IgM/IgA-enriched immunoglobulin preparation trimodulin on the complement pathway was investigated in in vitro opsonophagocytosis, binding and CDC assays. Immunoglobulin levels before and after trimodulin treatment were placed in relation to complement assessments in humans. In vitro, trimodulin activates complement and induces opsonophagocytosis, but also interacts with opsonins C3b, C4b and anaphylatoxin C5a in a concentration-dependent manner. This was not observed for standard intravenous IgG preparation (IVIg). Accordingly, trimodulin, but not IVIg, inhibited the downstream CDC pathway and target cell lysis. If applied at a similar concentration range in healthy subjects, trimodulin treatment resulted in C3 and C4 consumption in a concentration-dependent manner, which was extended in patients with severe community-acquired pneumonia. Complement consumption is found to be dependent on underlying immunoglobulin levels, particularly IgM, pinpointing their regulative function in humans. IgM/IgA provide a balancing effect on the complement system. Trimodulin may enhance phagocytosis and opsonophagocytosis in patients with severe infections and prevent excessive pathogen lysis and release of harmful anaphylatoxins.

10 November 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
CSCarolin Schmidt
Carolin Schmidt
SWSabrina Weißmüller
Sabrina Weißmüller
CHCorina C. Heinz
Corina C. Heinz
Severe infections induce immune defense mechanisms and initial tissue damage, which produce an inflammatory neutrophil response. Upon dysregulation of these responses, inflammation, further tissue damage, and systemic spread of the pathogen may occur. Subsequent vascular inflammation and activation of coagulation processes may cause microvascular obstruction at sites distal to the primary site of infection. Low immunoglobulin (Ig) M and IgG levels have been detected in patients with severe infections like sCAP and sepsis, associated with increased severity and mortality. Based on Ig’s modes of action, supplementation with polyvalent intravenous Ig preparations (standard IVIg or IgM/IgA-enriched Ig preparations) has long been discussed as a treatment option for severe infections. A prerequisite seems to be the timely administration of Ig preparations before excessive tissue damage has occurred and coagulopathy has developed. This review focuses on nonclinical and clinical studies that evaluated tissue-protective activities resulting from interactions of Igs with neutrophils, complement, and the coagulation system. The data indicate that coagulopathy, organ failure, and even death of patients can possibly be prevented by the timely combined interactions of (natural) IgM, IgA, and IgG with neutrophils and complement.

9 February 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
SWSabrina Weißmüller
Sabrina Weißmüller
CSCarolin Schmidt
Carolin Schmidt
CHCorina C. Heinz
Corina C. Heinz
In severe bacterial infections, endotoxin- and exotoxin-induced inflammation and tissue damage, combined with the consequent excessive production of inflammatory mediators by neutrophils, may result in sepsis, septic shock, organ failure, and possibly death. Evidence suggests that supplementation with polyvalent intravenous (IV) immunoglobulin (Ig) preparations, such as standard IVIg or IgM/IgA-enriched Ig preparations, could be an additional treatment option. However, their use in severe bacterial infections like sepsis and septic shock is still a matter of debate. This review summarizes the diverse beneficial mechanisms of (inter)actions of Igs with pathogens and the host. Support for these mechanisms comes from numerous nonclinical studies, complemented by clinical research in adult patients with sepsis, septic shock, and other severe infectious diseases. Depending on Ig type, timepoint of administration, patient population, and dose, the pathogen- and host-induced inflammatory responses are modulated by the combined (inter)actions of polyvalent IgM, IgA, and IgG, with pathogens, and particularly with the host’s neutrophil and complement pathways. However, while nonclinical and clinical studies suggest potential benefits of Ig therapy, clinical evidence remains heterogeneous, and trials with low risk of bias have not consistently demonstrated a definitive survival benefit. A deeper understanding of the conditions under which Ig treatment benefits patients with severe bacterial infections will help select patients most likely to profit from Ig treatment and achieve better outcomes.